FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017564843> ?p ?o ?g. }

• W2017564843 endingPage "426" @default.
• W2017564843 startingPage "422" @default.
• W2017564843 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Three ‘weak’ opioid analgesics are marketed in France and other European countries in association with paracetamol. • They are very largely used, but to our knowledge there is no large study comparing the reporting rate of adverse drug reactions (ADRs) between these different step 2 analgesic combinations to determine the safest one. WHAT THIS STUDY ADDS • The aim of this study was to compare reporting rate of ADRs with three step 2 combinations according to their consumption in France. • The results show that among these combinations, reporting rate and ‘seriousness’ of reported ADRs are the highest with tramadol/paracetamol (TRM+P) and the lowest with codeine/paracetamol. • The safety of TRM+P needs to be urgently investigated with more methodologically rigorous studies. AIMS Three ‘weak’ opioid analgesics in association with paracetamol are marketed in France as step 2 analgesics: dextropropoxyphene, tramadol and codeine. These combinations are involved in several adverse drug reactions (ADRs), but no data are available about their comparative reporting rate. The aim was to compare the reporting rate of ADRs between tramadol/paracetamol (TRM+P), codeine/paracetamol (COD+P) and dextropropoxyphene/paracetamol (DXP+P). METHODS All spontaneous reports submitted to the French Pharmacovigilance Database from 1 January 1987 to 31 December 2006 suspected to be induced by one of the three step 2 analgesic combinations (DXP+P, TRM+P, COD+P) were extracted. Their consumption for the same period was obtained from the French Drug Agency. The number of ADRs, serious ADRs and different organ classes of ADRs were compared according to their consumption. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each variable using DXP+P as reference. RESULTS The reporting rate of ADRs was calculated as 24.9/100 000 person‐years for DXP+P, 44.5/100 000 person‐years for TRM+P and 12.5/100 000 person‐years for COD+P. The reporting rate (OR 0.56, 95% CI 0.50, 0.63) and ‘seriousness»’ (OR 0.65, 95% CI 0.53, 0.80) of ADRs were significantly higher with TRM+P than with DXP+P. However, hepatobiliary ADRs were significantly more frequent with the DXP+P combination (OR 2.62, 95% CI 1.59, 4.37). In contrast, the reporting rate (OR 1.99, 95% CI 1.82, 2.18) and ‘seriousness’ (OR 2.64, 95% CI 2.24, 3.11) of ADRs were significantly higher with DXP+P than with COD+P. CONCLUSIONS Among the three step 2 analgesic combinations, reporting rate and ‘seriousness’ of ADRs are the highest with TRM+P and the lowest with COD+P. Our study suggests that the safety profile of DXP+P is worst than that of COD+P." @default.
• W2017564843 created "2016-06-24" @default.
• W2017564843 creator A5011154395 @default.
• W2017564843 creator A5050870063 @default.
• W2017564843 creator A5069068175 @default.
• W2017564843 creator A5091020739 @default.
• W2017564843 date "2009-09-01" @default.
• W2017564843 modified "2023-10-18" @default.
• W2017564843 title "Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol)" @default.
• W2017564843 cites W1594070576 @default.
• W2017564843 cites W1967891338 @default.
• W2017564843 cites W2014008304 @default.
• W2017564843 cites W2021582270 @default.
• W2017564843 cites W2058592440 @default.
• W2017564843 cites W2059219427 @default.
• W2017564843 cites W2064151584 @default.
• W2017564843 cites W2091062988 @default.
• W2017564843 cites W2153972688 @default.
• W2017564843 cites W2154080919 @default.
• W2017564843 cites W2155413620 @default.
• W2017564843 doi "https://doi.org/10.1111/j.1365-2125.2009.03472.x" @default.
• W2017564843 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2766482" @default.
• W2017564843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19740400" @default.
• W2017564843 hasPublicationYear "2009" @default.
• W2017564843 type Work @default.
• W2017564843 sameAs 2017564843 @default.
• W2017564843 citedByCount "31" @default.
• W2017564843 countsByYear W20175648432012 @default.
• W2017564843 countsByYear W20175648432013 @default.
• W2017564843 countsByYear W20175648432014 @default.
• W2017564843 countsByYear W20175648432015 @default.
• W2017564843 countsByYear W20175648432016 @default.
• W2017564843 countsByYear W20175648432017 @default.
• W2017564843 countsByYear W20175648432018 @default.
• W2017564843 countsByYear W20175648432019 @default.
• W2017564843 countsByYear W20175648432020 @default.
• W2017564843 countsByYear W20175648432021 @default.
• W2017564843 crossrefType "journal-article" @default.
• W2017564843 hasAuthorship W2017564843A5011154395 @default.
• W2017564843 hasAuthorship W2017564843A5050870063 @default.
• W2017564843 hasAuthorship W2017564843A5069068175 @default.
• W2017564843 hasAuthorship W2017564843A5091020739 @default.
• W2017564843 hasBestOaLocation W20175648432 @default.
• W2017564843 hasConcept C126322002 @default.
• W2017564843 hasConcept C170493617 @default.
• W2017564843 hasConcept C2777389121 @default.
• W2017564843 hasConcept C2777866328 @default.
• W2017564843 hasConcept C2778722691 @default.
• W2017564843 hasConcept C2778767360 @default.
• W2017564843 hasConcept C2779777798 @default.
• W2017564843 hasConcept C2780035454 @default.
• W2017564843 hasConcept C2780820201 @default.
• W2017564843 hasConcept C2781063702 @default.
• W2017564843 hasConcept C42219234 @default.
• W2017564843 hasConcept C508975757 @default.
• W2017564843 hasConcept C57658597 @default.
• W2017564843 hasConcept C71924100 @default.
• W2017564843 hasConcept C98274493 @default.
• W2017564843 hasConceptScore W2017564843C126322002 @default.
• W2017564843 hasConceptScore W2017564843C170493617 @default.
• W2017564843 hasConceptScore W2017564843C2777389121 @default.
• W2017564843 hasConceptScore W2017564843C2777866328 @default.
• W2017564843 hasConceptScore W2017564843C2778722691 @default.
• W2017564843 hasConceptScore W2017564843C2778767360 @default.
• W2017564843 hasConceptScore W2017564843C2779777798 @default.
• W2017564843 hasConceptScore W2017564843C2780035454 @default.
• W2017564843 hasConceptScore W2017564843C2780820201 @default.
• W2017564843 hasConceptScore W2017564843C2781063702 @default.
• W2017564843 hasConceptScore W2017564843C42219234 @default.
• W2017564843 hasConceptScore W2017564843C508975757 @default.
• W2017564843 hasConceptScore W2017564843C57658597 @default.
• W2017564843 hasConceptScore W2017564843C71924100 @default.
• W2017564843 hasConceptScore W2017564843C98274493 @default.
• W2017564843 hasIssue "3" @default.
• W2017564843 hasLocation W20175648431 @default.
• W2017564843 hasLocation W20175648432 @default.
• W2017564843 hasLocation W20175648433 @default.
• W2017564843 hasLocation W20175648434 @default.
• W2017564843 hasOpenAccess W2017564843 @default.
• W2017564843 hasPrimaryLocation W20175648431 @default.
• W2017564843 hasRelatedWork W1599988934 @default.
• W2017564843 hasRelatedWork W2416219562 @default.
• W2017564843 hasRelatedWork W2740295267 @default.
• W2017564843 hasRelatedWork W3036849654 @default.
• W2017564843 hasRelatedWork W3039309063 @default.
• W2017564843 hasRelatedWork W3049145683 @default.
• W2017564843 hasRelatedWork W4236928602 @default.
• W2017564843 hasRelatedWork W4285493781 @default.
• W2017564843 hasRelatedWork W4292808458 @default.
• W2017564843 hasRelatedWork W65300678 @default.
• W2017564843 hasVolume "68" @default.
• W2017564843 isParatext "false" @default.
• W2017564843 isRetracted "false" @default.
• W2017564843 magId "2017564843" @default.
• W2017564843 workType "article" @default.